<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04358016</url>
  </required_header>
  <id_info>
    <org_study_id>LDWJPMF-102-1700</org_study_id>
    <nct_id>NCT04358016</nct_id>
  </id_info>
  <brief_title>Terlipression Prevent Developing of Acute Kidney Injury During Upper-gastroentestinal Bleeding</brief_title>
  <official_title>The Protection of Telipression on Developing of Acute Kidney Injury in Cirrhotic Patients With Upper-gastroentestinal Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators studied the renal function index level in terlipressin treated cirrhotic
      patients with upper-gastrointestinal bleeding at different time point.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      54 cirrhotic patients with uppre-gastrointestinal bleeding were entrolled and were
      distributed into terlipressin group and control group at 1:1 rate. Patients in Terlipressin
      group received 1mg/6h of terlipressin intravenously for 5 days, and patients in control group
      recerved 1mg/12h of Somatostatin intravenously for 5 days.

      At enrollment, 24h,48h,72,and 1week, the renal function index level( serum creatinine,urine
      biochemistry and Urinary tubule injury index etc) were tested.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of acute kidney injure</measure>
    <time_frame>48 hours</time_frame>
    <description>serum creatinine level increased by 26.5umol/L during 48hours or increased 50% compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hemostasis rate</measure>
    <time_frame>48 hours</time_frame>
    <description>Fecal occult blood negative or hemoglobin stable after 48H treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of hepatic encephalopathy</measure>
    <time_frame>48 hours</time_frame>
    <description>Increased blood ammonia or directional force and computational power decrease after 48H treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of spontaneous bacterial peritonitis;</measure>
    <time_frame>48 hours</time_frame>
    <description>After 48H treatment, there is ascites and ascites has more than 20% nuclear cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of hyponatremia</measure>
    <time_frame>48 hours</time_frame>
    <description>Serum sodium levels below 130mmol/l</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Cirrhosis, Liver</condition>
  <condition>Upper Gastrointestinal Bleeding</condition>
  <arm_group>
    <arm_group_label>terlipression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>terlipression 1mg；once every 6 hours；5days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Somatostatin，3mg， once every 12 hours; 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>Evaluate the effect of Terlipression on the occurance of acute kidney injury in patients with upper-gastroentestinal bleeding</description>
    <arm_group_label>terlipression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatostatin</intervention_name>
    <description>Somatostatin</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosied as cirrhosis with upper gastrointestinal bleeding 18≤age≤70 Varicose vein
             rupture occurred within 24 hours, Without drug, endoscopy or interventional therapy
             Can read, understand and sign informed consent

        Exclusion Criteria:

          -  Pregnant women, lactating women; Serious cardiovascular disease: history of acute
             cardiac infarction, heart block, heart failure, arterial hypertension(（SBP＞170mmHg
             and/ or DBP＞100mmHg） Occlusive lower extremity venous disease Asthma, chronic
             obstructive pulmonary disease Have serious or unable to control other organ diseases;
             Cerebrovascular disease; Age ≥70 years old Known to be allergic to therapeutic drugs
             Chronic kidney disease Weight ≤40kg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuesong Liang, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Changhai hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>LiangXS</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>liver cirrhosis</keyword>
  <keyword>upper gastrointestinal bleeding</keyword>
  <keyword>acute kidney injury</keyword>
  <keyword>urinary IL-18</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

